Avantor/$AVTR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Avantor
Avantor Inc provides products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company operates through two segments: Laboratory Solutions and Bioscience Production. It offers materials & consumables, equipment & instrumentation, and services & specialty procurement. Product groups include Equipment & Instrumentation, Services & Specialty Procurement, Proprietary Materials & Consumables, and Third-Party Materials & Consumables. Materials & consumables include high-purity chemicals and reagents, lab supplies, customized excipients, single-use assemblies, chromatography products, sample preparation kits, and fluid handling solutions. It operates in the Americas, Europe, and AMEA.
- Ticker
- $AVTR
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 13,500
- Headquarters
- Radnor, United States
- Website
- www.avantorsciences.com
Avantor Metrics
BasicAdvanced
$11B
31.29
$0.50
0.94
-
Price and volume
Market cap
$11B
Beta
0.94
52-week high
$17.45
52-week low
$7.27
Average daily volume
9.9M
Financial strength
Current ratio
1.894
Quick ratio
1.159
Long term debt to equity
0.625
Total debt to equity
0.631
Interest coverage (TTM)
2.12%
Profitability
EBITDA (TTM)
947.6
Gross margin (TTM)
31.59%
Net profit margin (TTM)
5.08%
Operating margin (TTM)
7.96%
Effective tax rate (TTM)
-6.88%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
2.83%
Return on equity (TTM)
5.91%
Valuation
Price to earnings (TTM)
31.29
Price to revenue (TTM)
1.59
Price to book
1.81
Price to tangible book (TTM)
-5.22
Price to free cash flow (TTM)
24.023
Free cash flow yield (TTM)
4.16%
Free cash flow per share (TTM)
0.649
Growth
Revenue change (TTM)
0.92%
Earnings per share change (TTM)
-484.45%
3-year revenue growth (CAGR)
-1.95%
3-year earnings per share growth (CAGR)
-2.61%
What the Analysts think about Avantor
Analyst ratings (Buy, Hold, Sell) for Avantor stock.
Analyst projections of the future price of Avantor stock.
Bulls say / Bears say
Avantor returned to organic growth in Q3, with sales up 5.2% and both VWR and Bioscience & Medtech Products growing. That is a meaningful change after weak first-half trading. (Avantor)
Management raised its 2026 organic revenue growth, adjusted EPS and free cash flow outlook after Q3 outperformance. The higher forecast suggests the recovery is gaining traction, rather than being limited to one quarter. (Avantor)
Avantor generated $156.2 million of free cash flow in Q3 and reduced net debt by $173 million, taking adjusted net leverage to 3.1 times. Continued cash generation could strengthen the balance sheet and lower financing risk. (The Motley Fool)
VWR’s adjusted operating margin fell to 9.7% from 11.2%, as lower-margin sales mix and higher costs outweighed volume growth. Faster growth in this segment could keep weighing on group profitability. (Avantor)
Gross debt remained about $3.7 billion and adjusted net leverage was 3.1 times at quarter-end. That debt load leaves the business exposed if cash generation or the recovery falters. (Avantor)
Despite the Q3 rebound, Avantor’s full-year organic growth outlook is still only 0.75% to 1.25%, and Bioscience & Medtech Products is expected to be flat to slightly positive organically in Q4. This points to a recovery that remains uneven and vulnerable to segment-specific headwinds. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
Avantor Financial Performance
Revenues and expenses
Avantor Earnings Performance
Company profitability
Upcoming events
No upcoming events
Avantor News
AllArticlesVideos
Funds containing Avantor
AllUSDEURGBP
Fund name | Fund size | $AVTR weighting |
|---|---|---|
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.32% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.4B | 0.31% |
SPDR S&P 400 US Mid Cap£SPX4 | $6.4B | 0.31% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.21% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.21% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.